Comparing Innovation Spending: Biogen Inc. and ACADIA Pharmaceuticals Inc.

Biogen vs. ACADIA: A Decade of R&D Investment

__timestampACADIA Pharmaceuticals Inc.Biogen Inc.
Wednesday, January 1, 2014606020001893422000
Thursday, January 1, 2015738690002012800000
Friday, January 1, 2016992840001973300000
Sunday, January 1, 20171491890002253600000
Monday, January 1, 20181871630002597200000
Tuesday, January 1, 20192403850002280600000
Wednesday, January 1, 20203191300003990900000
Friday, January 1, 20212394150002501200000
Saturday, January 1, 20223615750002231100000
Sunday, January 1, 20233516190002702600000
Monday, January 1, 20242041800000
Loading chart...

Data in motion

Innovation in Biotech: A Tale of Two Companies

In the competitive world of biotechnology, innovation is the lifeblood of success. Over the past decade, Biogen Inc. and ACADIA Pharmaceuticals Inc. have demonstrated contrasting approaches to research and development (R&D) spending. Biogen, a giant in the industry, consistently invests heavily in R&D, with expenditures peaking at nearly $4 billion in 2020. This represents a staggering 110% increase from 2014. In contrast, ACADIA Pharmaceuticals, while smaller, has shown a remarkable growth trajectory, increasing its R&D spending by over 480% from 2014 to 2023. This strategic investment underscores ACADIA's commitment to innovation, despite its smaller scale. The data reveals a fascinating narrative of how two companies navigate the challenges of the biotech sector, with Biogen leveraging its resources for sustained innovation and ACADIA focusing on rapid growth and strategic investment.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025